Bacterial vaginosis biofilms: Challenges to current therapies and emerging solutions

Frontiers in Microbiology

Volumn 6, Issue JAN, 2016, Pages

  Machado, Daniela ^a   Castro, Joana ^a,b   Palmeira de Oliveira, Ana ^c,d   Martinez de Oliveira, José ^c,e   Cerca, Nuno ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^d Edifício UBIMEDICAL Estrada Municipal 506   (Portugal)

^e Centro Hospitalar Cova da Beira   (Portugal)

Author keywords

Antibiotics; Bacterial vaginosis; Biofilms; Emerging therapies; Gardnerella vaginalis

Indexed keywords

ACIDIFYING AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CLINDAMYCIN; LINCOSAMIDE; METRONIDAZOLE; ORNIDAZOLE; PLANT MEDICINAL PRODUCT; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; SECNIDAZOLE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ATOPOBIUM VAGINAE; BACTEROIDES; BIOFILM; GARDNERELLA VAGINALIS; HUMAN; MOBILUNCUS; NONHUMAN; PREVOTELLA; SHORT SURVEY; URINARY TRACT INFECTION; VAGINITIS;

EID: 84957990452     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01528     Document Type: Short Survey

References (130)

1. Abdali, K., Jahed, L., Amooee, S., Zarshenas, M., Tabatabaee, H., and Bekhradi, R. (2015). Comparison of the effect of vaginal Zataria multiflora cream and oral metronidazole pill on results of treatments for vaginal infections including trichomoniasis and bacterial vaginosis in women of reproductive age. Biomed. Res. Int. 2015:683640. doi: 10.1155/2015/683640.
2. Aguin, T., Akins, R. A., and Sobel, J. D. (2014). High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex. Transm. Dis. 41, 290-291. doi: 10.1097/OLQ.0000000000000123.
3. Algburi, A., Volski, A., and Chikindas, M. L. (2015). Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli. Pathog. Dis. 73:ftv018. doi: 10.1093/femspd/ftv018.
4. Alves, P., Castro, J., Sousa, C., Cereija, T. B., and Cerca, N. (2014). Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model. J. Infect. Dis. 210, 593-596. doi: 10.1093/infdis/jiu131.
5. Aroutcheva, A. A., Simoes, J. A., and Faro, S. (2001a). Antimicrobial protein produced by vaginal Lactobacillus acidophilus that inhibits Gardnerella vaginalis. Infect. Dis. Obstet. Gynecol. 9, 33-39. doi: 10.1155/S1064744901000060.
6. Aroutcheva, A., Gariti, D., Simon, M., Shott, S., Faro, J., Simoes, J. A., et al. (2001b). Defense factors of vaginal lactobacilli. Am. J. Obstet. Gynecol. 185, 375-379. doi: 10.1067/mob.2001.115867.
7. Bahamondes, M. V., Portugal, P. M., Brolazo, E. M., Simões, J. A., and Bahamondes, L. (2011). Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. Rev. Assoc. Med. Bras. 57, 415-420. doi: 10.1590/S0104-42302011000400015.
8. Beigi, R. H., Austin, M. N., Meyn, L. A., Krohn, M. A., and Hillier, S. L. (2004). Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynecol. 191, 1124-1129. doi: 10.1016/j.ajog.2004.05.033.
9. Blackwell, A. L. (1991). Tea tree oil and anaerobic (bacterial) vaginosis. Lancet 337, 300. doi: 10.1016/0140-6736(91)90910-H.
10. Bodean, O., Munteanu, O., Cirstoiu, C., Secara, D., and Cirstoiu, M. (2013). Probiotics-a helpful additional therapy for bacterial vaginosis. J. Med. Life 6, 434-436.
11. Bogavac, M., Karaman, M., Janjuševiæ, L. J., Sudji, J., Radovanoviæ, B., Novakoviæ, Z., et al. (2015). Alternative treatment of vaginal infections-in vitro antimicrobial and toxic effects of Coriandrum sativum L. and Thymus vulgaris L. essential oils. J. Appl. Microbiol. 119, 697-710. doi: 10.1111/jam.12883.
12. Bohbot, J.-M., Vicaut, E., Fagnen, D., and Brauman, M. (2010). Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect. Dis. Obstet. Gynecol. 2010:705692. doi: 10.1155/2010/705692.
13. Borges, S., Silva, J., and Teixeira, P. (2014). The role of lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 289, 479-489. doi: 10.1007/s00404-013-3064-9.
14. Boselli, F., Petrella, E., Campedelli, A., Muzi, M., Rullo, V., Ascione, L., et al. (2012). Efficacy and tolerability of fitostimoline (vaginal cream, ovules, and vaginal washing) and of benzydamine hydrochloride (tantum rosa vaginal cream and vaginal washing) in the topical treatment of symptoms of bacterial vaginosis. ISRN Obstet. Gynecol. 2012:183403. doi: 10.5402/2012/183403.
15. Boskey, E. R., Cone, R. A., Whaley, K. J., and Moench, T. R. (2001). Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum. Reprod. 16, 1809-1813. doi: 10.1093/humrep/16.9.1809.
16. Boskey, E. R., Telsch, K. M., Whaley, K. J., Moench, T. R., and Cone, R. A. (1999). Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect. Immun. 67, 5170-5175.
17. Bradshaw, C. S., Morton, A. N., Hocking, J., Garland, S. M., Morris, M. B., Moss, L. M., et al. (2006). High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 193, 1478-1486. doi: 10.1086/503780.
18. Braga, P. C., Sasso, M. D., Culici, M., and Spallino, A. (2010). Inhibitory activity of thymol on native and mature Gardnerella vaginalis biofilms: in vitro study. Arzneimittelforschung 60, 675-681. doi: 10.1055/s-0031-1296346.
19. Brotman, R. M., Klebanoff, M. A., Nansel, T. R., Yu, K. F., Andrews, W. W., Zhang, J., et al. (2010). Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J. Infect. Dis. 202, 1907-1915. doi: 10.1086/657320.
20. Cardone, A., Zarcone, R., Borrelli, A., Di-Cunzolo, A., Russo, A., and Tartaglia, E. (2003). Utilisation of hydrogen peroxide in the treatment of recurrent bacterial vaginosis. Minerva Ginecol. 55, 483-492.
21. Castro, J., and Cerca, N. (2015). BV and non-BV associated Gardnerella vaginalis establish similar synergistic interactions with other BV-associated microorganisms in dual-species biofilms. Anaerobe 36, 56-59. doi: 10.1016/j.anaerobe.2015.10.008.
22. Cavera, V. L., Volski, A., and Chikindas, M. L. (2015). The natural antimicrobial subtilosin A synergizes with lauramide arginine ethyl ester (LAE), ε-poly-l-lysine (polylysine), clindamycin phosphate and metronidazole, against the vaginal pathogen Gardnerella vaginalis. Probiotics Antimicrob. Proteins 7, 164-171. doi: 10.1007/s12602-014-9183-1.
23. Centers for Disease Control and Prevention (2015). Sexually Transmitted Diseases Treatment Guidelines, 2015. Atlanta, GA: Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services.
24. Cerca, N., Jefferson, K. K., Oliveira, R., Pier, G. B., and Azeredo, J. (2006). Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect. Immun. 74, 4849-4855. doi: 10.1128/IAI.00230-06.
25. Cerca, N., Martins, S., Cerca, F., Jefferson, K. K., Pier, G. B., Oliveira, R., et al. (2005). Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J. Antimicrob. Chemother. 56, 331-336. doi: 10.1093/jac/dki217.
26. Chavoustie, S. E., Jacobs, M., Reisman, H. A., Waldbaum, A. S., Levy, S. F., Hillier, S. L., et al. (2015). Metronidazole vaginal gel 1.3 % in the treatment of bacterial vaginosis?: a dose-ranging study. J. Low. Genit. Tract. Dis. 19, 129-134. doi: 10.1097/LGT.0000000000000062.
27. Cole, A. L., Herasimtschuk, A., Gupta, P., Waring, A. J., Lehrer, R. I., and Cole, A. M. (2007). The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology 121, 140-145. doi: 10.1111/j.1365-2567.2006.02553.x.
28. Coste, I., Judlin, P., Lepargneur, J. P., and Bou-Antoun, S. (2012). Safety and efficacy of an intravaginal prebiotic gel in the prevention of recurrent bacterial vaginosis: a randomized double-blind study. Obstet. Gynecol. Int. 2012:147867. doi: 10.1155/2012/147867.
29. Daniele, M., Pascual, L., and Barberis, L. (2014). Curative effect of the probiotic strain Lactobacillus fermentum L23 in a murine model of vaginal infection by Gardnerella vaginalis. Lett. Appl. Microbiol. 59, 93-98. doi: 10.1111/lam.12249.
30. Dickey, L. J., Nailor, M. D., and Sobel, J. D. (2009). Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. Ther. Clin. Risk Manag. 5, 485-489. doi: 10.2147/TCRM.S3777.
31. Donders, G. G. G., Guaschino, S., Peters, K., Tacchi, R., and Lauro, V. (2013). A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. Int. J. Gynecol. Obstet. 120, 131-136. doi: 10.1016/j.ijgo.2012.08.022.
32. Eade, C. R., Cole, A. L., Diaz, C., Rohan, L. C., Parniak, M. A., Marx, P., et al. (2013). The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa. Am. J. Reprod. Immunol. 69, 150-158. doi: 10.1111/aji.12036.
33. Facchinetti, F., Dante, G., Pedretti, L., Resasco, P., Annessi, E., and Dodero, D. (2013). The role of oral probiotic for bacterial vaginosis in pregnant women. A pilot study. Minerva Ginecol. 65, 215-221.
34. Falagas, M., Betsi, G. I., and Athanasiou, S. (2007). Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 13, 657-664. doi: 10.1111/j.1469-0691.2007.01688.x.
35. Gallo, M. F., Macaluso, M., Warner, L., Fleenor, M. E., Hook, E. W., Brill, I., et al. (2012). Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann. Epidemiol. 22, 213-220. doi: 10.1016/j.annepidem.2011.11.005.
36. Gardner, H. L., and Dukes, C. D. (1955). Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am. J. Obstet. Gynecol. 69, 962-976.
37. Gerli, S., Rossetti, D., and Di-Renzo, G. C. (2003). A new approach for the treatment of bacterial vaginosis: use of polyhexamethylene biguanide. A prospective, randomized study. Eur. Rev. Med. Pharmacol. Sci. 7, 127-130.
38. Guerra, B., Ghi, T., Quarta, S., Morselli-labate, A. M., Lazzarotto, T., Pilu, G., et al. (2006). Pregnancy outcome after early detection of bacterial vaginosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 128, 40-45. doi: 10.1016/j.ejogrb.2005.12.024.
39. Ha, Y. M., Choi, J. S., Lee, B. B., Moon, H. E., Cho, K. K., and Choi, I. S. (2014). Inhibitory effects of seaweed extracts on the growth of the vaginal bacterium Gardnerella vaginalis. J. Environ. Biol. 35, 537-542.
40. Hantoushzadeh, S., Golshahi, F., Javadian, P., Khazardoost, S., Aram, S., Hashemi, S., et al. (2012). Comparative efficacy of probiotic yoghurt and clindamycin in treatment of bacterial vaginosis in pregnant women: a randomized clinical trial. J. Matern. Neonatal. Med. 25, 1021-1024. doi: 10.3109/14767058.2011.614654.
41. Høiby, N., Ciofu, O., Johansen, H. K., Song, Z. J., Moser, C., Jensen, P. Ø., et al. (2011). The clinical impact of bacterial biofilms. Int. J. Oral Sci. 3, 55-65. doi: 10.4248/IJOS11026.
42. Holley, R. L., Richter, H. E., Varner, R. E., Pair, L., and Schwebke, J. R. (2004). A randomized, double-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis. Sex. Transm. Dis. 31, 236-238. doi: 10.1097/01.OLQ.0000118423.20985.E7.
43. Hooven, T. A., Randis, T. M., Hymes, S. R., Rampersaud, R., and Ratner, A. J. (2012). Retrocyclin inhibits Gardnerella vaginalis biofilm formation and toxin activity. J. Antimicrob. Chemother. 67, 2870-2872. doi: 10.1093/jac/dks305.
44. Hymes, S. R., Randis, T. M., Sun, T. Y., and Ratner, A. J. (2013). DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J. Infect. Dis. 207, 1491-1497. doi: 10.1093/infdis/jit047.
45. Ison, C. A., Taylor, R. F., Link, C., Buckett, P., Harris, J. R., and Easmon, C. S. (1987). Local treatment for bacterial vaginosis. Br. Med. J. 295:886. doi: 10.1136/bmj.295.6603.886.
46. Jacobsson, B., Pernevi, P., Chidekel, L., and Platz-Christensen, J. J. (2002). Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. Acta Obstet. Gynecol. Scand. 81, 1006-1010. doi: 10.1034/j.1600-0412.2002.811103.x.
47. Josey, W. E., and Schwebke, J. R. (2008). The polymicrobial hypothesis of bacterial vaginosis causation: a reassessment. Int. J. STD AIDS 19, 152-154. doi: 10.1258/ijsa.2007.007260.
48. Kaewnopparat, S., Dangmanee, N., Kaewnopparat, N., Srichana, T., Chulasiri, M., and Settharaksa, S. (2013). In vitro probiotic properties of Lactobacillus fermentum SK5 isolated from vagina of a healthy woman. Anaerobe 22, 6-13. doi: 10.1016/j.anaerobe.2013.04.009.
49. Kaur, B., Balgir, P. P., Mittu, B., Kumar, B., and Garg, N. (2013). Biomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770. Biomed Res. Int. 2013:168438. doi: 10.1155/2013/168438.
50. Koumans, E. H., Sternberg, M., Bruce, C., McQuillan, G., Kendrick, J., Sutton, M., et al. (2007). The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex. Transm. Dis. 34, 864-869. doi: 10.1097/OLQ.0b013e318074e565.
51. Kovachev, S., and Dobrevski-Vacheva, R. (2013). Effect of Lactobacillus casei var rhamnosus (Gynophilus) in restoring the vaginal flora by female patients with bacterial vaginosis-randomized, open clinical trial. Akush. Ginekol. (Sofiia). 1, 48-53.
52. Kovachev, S., and Vatcheva-Dobrevski, R. (2013). Efficacy of combined 5-nitroimidazole and probiotic therapy of bacterial vaginosis: randomized open trial. Akush. Ginekol. (Sofiia). 52, 19-26.
53. Krasnopolsky, V. N., Prilepskaya, V. N., Polatti, F., Zarochentseva, N. V., Bayramovab, G. R., Caserinid, M., et al. (2013). Efficacy of vitamin C vaginal tablets as prophylaxis for recurrent bacterial vaginosis?: a randomised. J. Clin. Med. Res. 5, 309-315. doi: 10.4021/jocmr1489w.
54. Lachapelle, J., Castel, O., Casado, A. F., Leroy, B., Micali, G., Tennstedt, D., et al. (2013). Antiseptics in the era of bacterial resistance?: a focus on povidone iodine. Clin. Pract. 10, 579-592. doi: 10.2217/cpr.13.50.
55. Leite, S. R. R. F., Amorim, M. M. R., Sereno, P. F. B., Leite, T. N. F., Ferreira, J. A. C., and Ximenes, R. A. A. (2011). Randomized clinical trial comparing the efficacy of the vaginal use of metronidazole with a Brazilian pepper tree (Schinus) extract for the treatment of bacterial vaginosis. Braz. J. Med. Biol. Res. 44, 245-252. doi: 10.1590/S0100-879X2011007500003.
56. Leitich, H., Bodner-Adler, B., Brunbauer, M., Kaider, A., Egarter, C., and Husslein, P. (2003). Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 189, 139-147. doi: 10.1067/mob.2003.339.
57. Ling, Z., Liu, X., Chen, W., Luo, Y., Yuan, L., Xia, Y., et al. (2013). The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics. Microb. Ecol. 65, 773-780. doi: 10.1007/s00248-012-0154-3.
58. Machado, A., and Cerca, N. (2015). The influence of biofilm formation by Gardnerella vaginalis and other anaerobes on bacterial vaginosis. J. Infect. Dis. doi: 10.1093/infdis/jiv338.
59. Machado, A., Salgueiro, D., Harwich, M., Jefferson, K. K., and Cerca, N. (2013). Quantitative analysis of initial adhesion of bacterial vaginosis-associated anaerobes to ME-180 cells. Anaerobe 23, 1-4. doi: 10.1016/j.anaerobe.2013.07.007.
60. Marcone, V., Rocca, G., Lichtner, M., and Calzolari, E. (2010). Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int. J. Gynaecol. Obstet. 110, 223-226. doi: 10.1016/j.ijgo.2010.04.025.
61. Marrazzo, J. M., Koutsky, L. A., Eschenbach, D. A., Agnew, K., Stine, K., and Hillier, S. L. (2002). Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J. Infect. Dis. 185, 1307-1313. doi: 10.1086/339884.
62. Mastromarino, P., Brigidi, P., Macchia, S., Maggi, L., Pirovano, F., Trinchieri, V., et al. (2002). Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J. Appl. Microbiol. 93, 884-893. doi: 10.1046/j.1365-2672.2002.01759.x.
63. McClelland, R. S., Balkus, J. E., Lee, J., Anzala, O., Kimani, J., Schwebke, J., et al. (2015). Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J. Infect. Dis. 211, 1875-1882. doi: 10.1093/infdis/jiu818.
64. McMillan, A., Dell, M., Zellar, M. P., Cribby, S., Martz, S., Hong, E., et al. (2011). Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces 86, 58-64. doi: 10.1016/j.colsurfb.2011.03.016.
65. Menard, J. P. (2011). Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int. J. Womens Health 3, 295-305. doi: 10.2147/IJWH.S23814.
66. Milani, M., Molteni, B., and Silvani, I. (2000). Effect on vaginal pH of a polycarbophil vaginal gel compared with an acidific douche in women with suspected bacterial vaginosis: a randomized, controlled study. Curr. Ther. Res. 61, 781-788. doi: 10.1016/S0011-393X(00)90004-3.
67. Moffett, M., and Mcgill, M. I. (1960). Treatment of trichomoniasis with metronidazole. Br. Med. J. 24, 910-911. doi: 10.1136/bmj.2.5203.910.
68. Mohammadzadeh, F., Dolatian, M., Jorjani, M., Alavi Majd, H., and Borumandnia, N. (2014). Comparing the therapeutic effects of garlic tablet and oral metronidazole on bacterial vaginosis: a randomized controlled clinical trial. Iran. Red. Crescent. Med. J. 16:e19118. doi: 10.5812/ircmj.19118.
69. Molteni, B., D'Antuono, A., Bandini, P., Sintini, G., Barcellona, E., Agnello, A., et al. (2004). Efficacy and tolerability of a new chlorhexidine-based vaginal gel in vaginal infections. Curr. Med. Res. Opin. 20, 849-853. doi: 10.1185/030079904125003692.
70. Naidoo, D., van Vuuren, S. F., van Zyl, R. L., and de Wet, H. (2013). Plants traditionally used individually and in combination to treat sexually transmitted infections in northern Maputaland, South Africa: antimicrobial activity and cytotoxicity. J. Ethnopharmacol. 149, 656-667. doi: 10.1016/j.jep.2013.07.018.
71. Nikolov, A., Shopova, E., Nashar, S., and Dimitrov, A. (2008). Application of sumamed in treatment of bacterial vaginal infections during pregnancy. Akush. Ginekol. (Sofiia). 47, 7-10.
72. Novakov Mikic, A., and Budakov, D. (2010). Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch. Gynecol. Obstet. 282, 43-47. doi: 10.1007/s00404-009-1241-7.
73. Núñez, J. T., and Gómez, G. (2005). Low-dose secnidazole in the treatment of bacterial vaginosis. Int. J. Gynaecol. Obstet. 88, 281-285. doi: 10.1016/j.ijgo.2004.11.028.
74. Otsuki, K., Tokunaka, M., Oba, T., Nakamura, M., Shirato, N., and Okai, T. (2014). Administration of oral and vaginal prebiotic lactoferrin for a woman with a refractory vaginitis recurring preterm delivery: appearance of Lactobacillus in vaginal flora followed by term delivery. J. Obstet. Gynaecol. Res. 40, 583-585. doi: 10.1111/jog.12171.
75. Paavonen, J., Mangioni, C., Martin, M. A., and Wajszczuk, C. P. (2000). Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet. Gynecol. 96, 256-260. doi: 10.1016/S0029-7844(00)00902-9.
76. Palmeira-de-Oliveira, A., Gaspar, C., Palmeira-de-Oliveira, R., Silva-Dias, A., Salgueiro, L., Cavaleiro, C., et al. (2012). The anti-Candida activity of Thymbra capitata essential oil: effect upon pre-formed biofilm. J. Ethnopharmacol. 140, 379-383. doi: 10.1016/j.jep.2012.01.029.
77. Palmeira-de-Oliveira, A., Silva, B. M., Palmeira-de-Oliveira, R., Martinez-de-Oliveira, J., and Salgueiro, L. (2013). Are Plant Extracts a Potential Therapeutic Approach for Genital Infections? Curr. Med. Chem. 20, 2914-2928. doi: 10.2174/09298673113209990007.
78. Patel, Y., Gopalan, S., Bagga, R., Sharma, M., Chopra, S., and Sethi, S. (2008). A randomized trial comparing a polyherbal pessary (a complementary and alternative medicine) with Ginlac-V pessary (containing clotrimazole, tinidazole and lactobacilli) for treatment of women with symptomatic vaginal discharge. Arch. Gynecol. Obstet. 278, 341-347. doi: 10.1007/s00404-008-0568-9.
79. Patterson, J. L., Girerd, P. H., Karjane, N. W., and Jefferson, K. K. (2007). Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am. J. Obstet. Gynecol. 197, e1-e7. doi: 10.1016/j.ajog.2007.02.027.
80. Pendharkar, S., Brandsborg, E., Hammarström, L., Marcotte, H., and Larsson, P. G. (2015). Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infect. Dis. 15, 255. doi: 10.1186/s12879-015-0971-3.
81. Petersen, E. E., Genet, M., Caserini, M., and Palmieri, R. (2011). Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial. Arzneimittelforschung 61, 260-265. doi: 10.1055/s-0031-1296197.
82. Petersen, E. E., Weissenbacher, E. R., Hengst, P., Spitzbart, H., Weise, W. W., Wolff, F., et al. (2002). Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung 52, 706-715. doi: 10.1055/s-0031-1299955.
83. Pirotta, M., Fethers, K. A., and Bradshaw, C. S. (2009). Bacterial vaginosis more questions than answers. Aust. Fam. Phys. 38, 394-397.
84. Polatti, F., Rampino, M., Magnani, P., and Mascarucci, P. (2006). Vaginal pH-lowering effect of locally applied vitamin C in subjects with high vaginal pH. Gynecol. Endocrinol. 22, 230-234. doi: 10.1080/09513590600647441.
85. Ratzan, J. J. (1969). Monilial and trichomonal vaginitis. Topical treatment with povidone-iodine preparations. Calif. Med. 110, 24-27.
86. Ravel, J., Gajer, P., Abdo, Z., Schneider, G. M., Koenig, S. S. K., McCulle, S. L., et al. (2011). Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U.S.A. 108, 4680-4687. doi: 10.1073/pnas.1002611107.
87. Recine, N., Palma, E., Domenici, L., Giorgini, M., Imperiale, L., Sassu, C., et al. (2016). Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch. Gynecol. Obstet. 293, 101-107. doi: 10.1007/s00404-015-3810-2.
88. Reichman, O., Akins, R., and Sobel, J. D. (2009). Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm. Dis. 36, 732-734. doi: 10.1097/OLQ.0b013e3181b08456.
89. Riazi, S., Dover, S. E., and Chikindas, M. L. (2012). Mode of action and safety of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050. J. Appl. Microbiol. 113, 714-722. doi: 10.1111/j.1365-2672.2012.05376.x.
90. Roberfroid, M. (2007). Prebiotics: the concept revisited. J. Nutr. 137, 830S-837S.
91. Rosen, A. D., and Rosen, T. (1999). Study of condom integrity after brief exposure to over-the-counter vaginal preparations. South. Med. J. 92, 305-307. doi: 10.1097/00007611-199903000-00009.
92. Rossi, A., Rossi, T., Bertini, M., and Caccia, G. (2010). The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch. Gynecol. Obstet. 281, 1065-1069. doi: 10.1007/s00404-009-1287-6.
93. Rothman, K. J., Funch, D. P., Alfredson, T., Brady, J., and Dreyer, N. A. (2003). Randomized field trial of vaginal douching, pelvic inflammatory disease and pregnancy. Epidemiology 14, 340-348. doi: 10.1097/01.EDE.0000059230.67557.D3.
94. Rousseau, V., Lepargneur, J. P., Roques, C., Remaud-Simeon, M., and Paul, F. (2005). Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. Anaerobe 11, 145-153. doi: 10.1016/j.anaerobe.2004.12.002.
95. Saunders, S., Bocking, A., Challis, J., and Reid, G. (2007). Effect of Lactobacillus challenge on Gardnerella vaginalis biofilms. Colloids Surf. B Biosurf. 55, 138-142. doi: 10.1016/j.colsurfb.2006.11.040.
96. Schwebke, J. R., and Desmond, R. A. (2011). Tinidazole versus metronidazole for treatment of bacterial vaginosis. Am. J. Obstet. Gynecol. 204, 211e1-211e6. doi: 10.1016/j.ajog.2010.10.898.
97. Schwebke, J. R., Marrazzo, J., Andrew, P., and Sobel, J. D. (2015). A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm. Dis. 42, 376-381. doi: 10.1097/OLQ.0000000000000300.
98. Schwebke, J. R., Muzny, C. A., and Josey, W. E. (2014). Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J. Infect. Dis. 210, 338-343. doi: 10.1093/infdis/jiu089.
99. Shaaban, O. M., Fetih, G. N., Abdellah, N. H., Ismail, S., Ibrahim, M. A., and Ibrahim, E. A. (2011). Pilot randomized trial for treatment of bacterial vaginosis using in situ forming metronidazole vaginal gel. J. Obstet. Gynaecol. Res. 37, 874-881. doi: 10.1111/j.1447-0756.2010.01457.x.
100. Simoes, J. A., Bahamondes, L. G., Camargo, R. P. S., Alves, V. M. N., Zaneveld, L. J. D., Waller, D. P., et al. (2006). A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. Br. J. Clin. Pharmacol. 61, 211-217. doi: 10.1111/j.1365-2125.2005.02550.x.
101. Sobel, J. D. (2000). Bacterial vaginosis. Annu. Rev. Med. 51, 349-356. doi: 10.1146/annurev.med.51.1.349.
102. Sosto, F., Benvenuti, C., and CANVA Study Group (2011). Controlled study on thymol + eugenol vaginal douche versus econazole in vaginal candidiasis and metronidazole in bacterial vaginosis. Arzneimittelforschung 61, 126-131. doi: 10.1055/s-0031-1296178.
103. Strandberg, K. L., Peterson, M. L., Lin, Y.-C., Pack, M. C., Chase, D. J., and Schlievert, P. M. (2010). Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob. Agents Chemother. 54, 597-601. doi: 10.1128/AAC.01151-09.
104. Sundara Rajan, S., Cavera, V. L., Zhang, X., Singh, Y., Chikindas, M. L., and Sinko, P. J. (2014). Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis. Antimicrob. Agents Chemother. 58, 2747-2753. doi: 10.1128/AAC.02446-14.
105. Sutyak, K. E., Wirawan, R. E., Aroutcheva, A. A., and Chikindas, M. L. (2008). Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J. Appl. Microbiol. 104, 1067-1074. doi: 10.1111/j.1365-2672.2007.03626.x.
106. Sutyak, K. N., Prichard, M. N., Khaykin, A., Sinko, P. J., and Chikindas, M. L. (2012). The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and-poly-l-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli. Antimicrob. Agents Chemother. 56, 1756-1761. doi: 10.1128/AAC.05861-11.
107. Swidsinski, A., Loening-Baucke, V., Swidsinski, S., and Verstraelen, H. (2015). Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch. Gynecol. Obstet. 291, 605-609. doi: 10.1007/s00404-014-3484-1.
108. Swidsinski, A., Mendling, W., Loening-Baucke, V., Ladhoff, A., Swidsinski, S., Hale, L. P., et al. (2005). Adherent biofilms in bacterial vaginosis. Obstet. Gynecol. 106, 1013-1023. doi: 10.1097/01.AOG.0000183594.45524.d2.
109. Swidsinski, A., Mendling, W., Loening-Baucke, V., Swidsinski, S., Dörffel, Y., Scholze, J., et al. (2008). An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 198, 97.e1-e6. doi: 10.1016/j.ajog.2007.06.039.
110. Taheri, M., Baheiraei, A., Foroushani, A. R., Nikmanesh, B., and Modarres, M. (2015). Treatment of vitamin D deficiency is an effective method in the elimination of asymptomatic bacterial vaginosis: a placebo-controlled randomized clinical trial. Indian J. Med. Res. 141, 799-806. doi: 10.4103/0971-5916.160707.
111. Tally, F. P., Sutter, V. L., and Finegold, S. M. (1975). Treatment of anaerobic infections with metronidazole. Antimicrob. Agents Chemother. 7, 672-675. doi: 10.1128/AAC.7.5.672.
112. Thulkar, J., Kriplani, A., and Agarwal, N. (2012). A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J. Pharmacol. 44, 243-245. doi: 10.4103/0253-7613.93859.
113. Tobudic, S., Kratzer, C., Lassnigg, A., and Presterl, E. (2012). Antifungal susceptibility of Candida albicans in biofilms. Mycoses 55, 199-204. doi: 10.1111/j.1439-0507.2011.02076.x.
114. Togni, G., Battini, V., Bulgheroni, A., Mailland, F., Caserini, M., and Mendling, W. (2011). In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis? Antimicrob. Agents Chemother. 55, 2490-2492. doi: 10.1128/AAC.01623-10.
115. Trexler, M. F., Fraser, T. G., and Jones, M. P. (1997). Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream. Am. J. Gastroenterol. 92, 2112-2113.
116. Turner, A. N., Carr Reese, P., Fields, K. S., Anderson, J., Ervin, M., Davis, J. A., et al. (2014). A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am. J. Obstet. Gynecol. 211, 479.e1-e13. doi: 10.1016/j.ajog.2014.06.023.
117. Turovskiy, Y., Cheryian, T., Algburi, A., Wirawan, R. E., Takhistov, P., Sinko, P. J., et al. (2012). Susceptibility of Gardnerella vaginalis biofilms to natural antimicrobials subtilosin, e-poly-L-Lysine, and lauramide arginine ethyl ester. Infect. Dis. Obstet. Gynecol. 2012:284762. doi: 10.1155/2012/284762.
118. Turovskiy, Y., Ludescher, R. D., Aroutcheva, A. A., Faro, S., and Chikindas, M. L. (2009). Lactocin 160, a bacteriocin produced by vaginal Lactobacillus rhamnosus, targets cytoplasmic membranes of the vaginal pathogen, Gardnerella vaginalis. Probiotics Antimicrob. Proteins 1, 67-74. doi: 10.1007/s12602-008-9003-6.
119. Food and Agriculture Organization of the United Nations and World Health Organization (2001). Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Córdoba.
120. Van Slyke, K. K., Michel, V. P., and Rein, M. F. (1981). Treatment of vulvovaginal candidiasis with boric acid powder. Am. J. Obstet. Gynecol. 141, 145-148.
121. Verhelst, R., Verstraelen, H., Claeys, G., Verschraegen, G., Delanghe, J., Van Simaey, L., et al. (2004). Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol. 4:16. doi: 10.1186/1471-2180-4-16.
122. Verstraelen, H., Verhelst, R., Roelens, K., and Temmerman, M. (2012). Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect. Dis. 12:148. doi: 10.1186/1471-2334-12-148.
123. Vicariotto, F., Mogna, L., and Del Piano, M. (2014). Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis A Pilot Study. J. Clin. Gastroenterol. 48, S106-S112. doi: 10.1097/MCG.0000000000000226.
124. Vujic, G., Knez, A. J., Stefanovic, V. D., and Vrbanovic, V. K. (2013). Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 168, 75-79. doi: 10.1016/j.ejogrb.2012.12.031.
125. Wewalka, G., Stary, A., Bosse, B., Duerr, H. E., and Reimer, K. (2002). Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology 204, 79-85. doi: 10.1159/000057731.
126. Wood, B. A., and Monro, A. M. (1975). Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br. J. Vener. Dis. 51, 51-53. doi: 10.1136/sti.51.1.51.
127. Xie, Z., Thompson, A., Sobue, T., Kashleva, H., Xu, H., Vasilakos, J., et al. (2012). Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing. J. Infect. Dis. 206, 1936-1945. doi: 10.1093/infdis/jis607.
128. Xu, S., Cavera, V. L., Rogers, M. A., Huang, Q., Zubovskiy, K., and Chikindas, M. L. (2013). Benzoyl peroxide formulated polycarbophil/carbopol 934P hydrogel with selective antimicrobial activity, potentially beneficial for treatment and prevention of bacterial vaginosis. Infect. Dis. Obstet. Gynecol. 2013:909354. doi: 10.1155/2013/909354.
129. Zeng, Z. M., Liao, Q. P., Yao, C., Geng, L., Feng, L. H., Shi, H. R., et al. (2010). Directed shift of vaginal flora after topical application of sucrose gel in a phase III clinical trial: a novel treatment for bacterial vaginosis. Chin. Med. J. (Engl.) 123, 2051-2057.
130. Zodzika, J., Rezeberga, D., Donders, G., Vedmedovska, N., Vasina, O., Pundure, I., et al. (2013). Impact of vaginal ascorbic acid on abnormal vaginal microflora. Arch. Gynecol. Obstet. 288, 1039-1044. doi: 10.1007/s00404-013-2876-y.